Endocrine studies in an arrhenoblastoma responsive to dexamethasone, ACTH and human chorionic gonadotropin

The hormone pattern in a case of arrhenoblastoma

“…Removal of the t u m o u r in our patient was followed by normalization of plasma androgens, as already shown by Tucci et al (1973) and of plasma oestrogens followed by menarche and regular ovulatory menses.…”

“…Between 1965 and the present day a further 6 cases under 18 years have been reported in literature (Okun 1965;Ehrlich et al 1968;Goldstein and Lamb 1970;Mahesh et al 1970;Greenblatt et al 1972 Few detailed hormonal studies have appeared even in patients over 18 years old; plasma testosterone has been found to be elevated (Mahesh et al 1970;Greenblatt et al 1972;Tucci et al 1973) and urinary 17 KS normal or high (Podowitz and O'Brien 1960;Gallagher et al 1962;Louros et al 1966). …”

Long-Term Suppression of Testosterone After Treatment with a Gonadotropin-Releasing Hormone Agonist in a Woman with a Presumed Testosterone Secreting Ovarian Tumor

“…Our patient responded to nafarelin with an approximately 2-fold increase in 17-hydroxyprogesterone and androstenedione; however, she was unusual, but not unique, in that testosterone was unchanged (9). These tumors also respond to treatment with the oral contraceptive pill, with testosterone suppressing to normal or near normal levels in some (16 -20) but not all cases (13,14).…”

“…CG stimulation has been reported to result in a 1.5-to 10-fold increase in 17-hydroxyprogesterone, andro- stenedione, and testosterone (7,8,(13)(14)(15)(16)(17). Our patient responded to nafarelin with an approximately 2-fold increase in 17-hydroxyprogesterone and androstenedione; however, she was unusual, but not unique, in that testosterone was unchanged (9).…”

Short Term Administration of Gonadotropin-Releasing Hormone Analog to a Patient with a Testosterone-Secreting Ovarian Tumor

“…In many of these patients the secretion of androgens may be stimulated by gonadotropins, whereas responses to ACTH, estrogens, and dexamethasone have been much more variable (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12). In this report we describe a postmenopausal woman with a Leydig cell tumor of the ovary in whom serum testosterone levels decreased markedly during the administration of buserelin (D-Ser[TBU] 6 -des-Gly-NH 2 10 -LHRH nonapeptide ethylamide, Hoechst AG, Frankfurt/Main, West Germany), a GnRH superagonist with approximately 40 times the potency of GnRH (13).…”